JapanStake
Pharmaceutical · Fiscal year end Mar 31

Mochida Pharmaceutical Co.,Ltd.

4534

持田製薬株式会社

FIGI BBG000BJYBV94534.T4534 JPCorp. no. 9011101021173

Latest half-year results

First half · fiscal year to 2026-03 · filed 2025-11-10

For the first half of the fiscal year to 2026-03: Revenue ¥55 billion (+7.6% YoY), Ordinary income ¥5.2 billion (+27.0% YoY), Net income ¥3.9 billion (+36.5% YoY).

This periodYear on year
Revenue¥55.0bn+7.6%
Ordinary profit¥5.2bn+27.0%
Net profit to owners¥3.9bn+36.5%

From the securities report on EDINET, which states no forecast. History via /v1/companies/4534/earnings-releases.

Financials

Japan GAAP · consolidated · fiscal year to 2026-03-31
Revenue
¥117.0bn
Net income
¥7.9bn
ROE
5.8%
Equity ratio
76.8%
Dividend / share
¥80
Employees
1,479
Revenue · ¥bn
FY2022: ¥110.2bn 110 FY2022FY2023: ¥103.3bn 103 FY2023FY2024: ¥102.9bn 103 FY2024FY2025: ¥105.2bn 105 FY2025FY2026: ¥117.0bn 117 FY2026
Net income · ¥bn
FY2022: ¥10.6bn 10.6 FY2022FY2023: ¥6.6bn 6.65 FY2023FY2024: ¥4.5bn 4.55 FY2024FY2025: ¥5.7bn 5.69 FY2025FY2026: ¥7.9bn 7.9 FY2026
Fiscal yearRevenueNet incomeTotal assetsNet assetsROEEPSOperating CF
2026-03-31¥117.0bn¥7.9bn¥182.7bn¥140.3bn5.8%¥222.96−¥7.4bn
2025-03-31¥105.2bn¥5.7bn¥160.1bn¥130.7bn4.4%¥160.36¥9.4bn
2024-03-31¥102.9bn¥4.5bn¥158.8bn¥128.0bn3.6%¥126.8−¥7.5bn
2023-03-31¥103.3bn¥6.6bn¥158.8bn¥126.8bn5.2%¥178.93¥7.3bn
2022-03-31¥110.2bn¥10.6bn¥163.1bn¥128.6bn8.3%¥277.39¥7.5bn

Indicators

Computed by us from filings · fiscal year to 2026-03-31
MetricValuePercentile among listed companies
ROE, %5.830.5
Ordinary margin0.095766
Equity ratio, %76.885.8
Revenue growth0.112172.5
Net income growth0.390170.5
Operating cash flow / assets-0.04029
Policy-uncertainty measure1.54 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.
Regulation 2 Politics & geopolitics 2
Ownership activity 0 filer(s) stated they may make proposals in 365 days; 0 new 5% holder(s) in 180 days; net stake change 0.00pt in 90 days; 7.0% held by other listed companies.

Results wording balance: +0.65. Proprietary text method; it describes the wording only and does not interpret context.

Interest example: if all ¥10.0bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥50m. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.

Via /v1/companies/4534/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them
Share buyback, report to —: ¥1.1bn acquired of a ¥2.0bn limit. /v1/companies/4534/buybacks
Internal control, 2026-06-24: see filing 上記の評価の結果、当連結会計年度の末日時点において、当社の財務報告に係る内部統制は有効であると判断いたしました。 Filing

Segments, votes and tender offers

Stated in EDINET filings
Latest voting result: 2026-06-25 · 剰余金の処分の件 · passed. /v1/companies/4534/voting

Ownership changes

All companies →

5% filings

Large shareholding reports on 4534
FiledFilerStakeChangeStated purpose
2026-04-10Mochida Memorial Foundation for Medical and Pharmaceutical Research15.63%+1.63pt—
2024-07-29Mitsubishi UFJ Financial Group, Inc.5.72%−0.23ptstrategic holding
2022-11-08Mitsubishi UFJ Financial Group, Inc.5.95%−0.93ptstrategic holding
2022-10-07Mizuho Bank,Ltd.5.48%−0.83pt—

Cross-shareholdings

From the annual report's status of shareholdings
Listed strategic holdings
12 issues
Book value
¥21.1bn
Sold in the year
— — issues
Bought in the year
— — issues
Mutual, both reports
9
Held by listed cos.
13
HoldsBook valueShares vs. prior yearMutual
Nissui Corporation 1332¥10.7bn0.0%both reports
Sumitomo Pharma Co., Ltd. 4506¥1.9bn0.0%both reports
Alfresa Holdings Corporation 2784¥1.8bn0.0%both reports
Mitsubishi UFJ Financial Group, Inc. 8306¥1.6bn0.0%no
JCR Pharmaceuticals Co.,Ltd. 4552¥1.2bn0.0%both reports
TOHO HOLDINGS CO.,LTD. 8129¥1.2bn0.0%both reports
SUZUKEN CO.,LTD. 9987¥1.0bn0.0%both reports
MEDIPAL HOLDINGS CORPORATION 7459¥0.9bn0.0%both reports
Mizuho Financial Group, Inc. 8411¥0.3bn0.0%no
㈱ほくやく・竹山ホールディングス¥0.2bn0.0%no

Held by: Nissui Corporation 1332, Sumitomo Pharma Co., Ltd. 4506, JCR Pharmaceuticals Co.,Ltd. 4552, Alfresa Holdings Corporation 2784, TOHO HOLDINGS CO.,LTD. 8129, SUZUKEN CO.,LTD. 9987, TSUMUGU Holdings, Inc. 3055, MEDIPAL HOLDINGS CORPORATION 7459, VITAL KSK HOLDINGS,INC. 3151, TODA CORPORATION 1860, VITAL KSK HOLDINGS,INC. 3151, ASAHI PRINTING CO.,LTD. 3951 and 2 more

Purposes, all holdings and mutual flags via /v1/companies/4534/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2026-03-31
ShareholderSharesRatio
公益財団法人持田記念医学薬学振興財団5,688,00016.05%
日本マスタートラスト信託銀行株式会社(信託口)2,981,0008.41%
公益財団法人高松宮妃癌研究基金1,683,0004.75%
株式会社三菱UFJ銀行1,586,0004.48%
みずほ信託銀行株式会社　退職給付信託みずほ銀行口　再信託受託者株式会社日本カストディ銀行1,434,0004.05%
株式会社ニッスイ1,200,0003.39%
individual holder1,023,0002.89%
individual holder949,0002.68%
individual holder787,0002.22%
大正製薬ホールディングス株式会社785,0002.21%

U.S. funds holding 4534

SEC Form N-PORT, reports to 2026-07-31

48 U.S. funds held 1,449,627 shares worth $28.6m.

FundSharesValue% of fundAs of
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND
VANGUARD STAR FUNDS
316,158$6.2m0.001%2026-07-31
VANGUARD DEVELOPED MARKETS INDEX FUND
VANGUARD TAX-MANAGED FUNDS
209,162$4.1m0.001%2026-06-30
iShares Core MSCI EAFE ETF
iShares Trust
134,900$2.6m0.001%2026-07-31
VANGUARD FTSE ALL-WORLD EX-US SMALL-CAP INDEX FUND
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS
83,500$1.6m0.012%2026-07-31
iShares MSCI EAFE Small-Cap ETF
iShares Trust
73,700$1.4m0.011%2026-07-31

Up to 25 funds per stock via the API.

Get this as JSON

GET /v1/companies/4534
GET /v1/companies/4534/financials
GET /v1/companies/4534/details
GET /v1/companies/4534/segments
GET /v1/companies/4534/voting
GET /v1/companies/4534/tender-offers
GET /v1/companies/4534/indicators
GET /v1/companies/4534/earnings-releases
GET /v1/events?ticker=4534
GET /v1/companies/4534/trades         
GET /v1/companies/4534/cross-holdings 
GET /v1/companies/4534/brief

Plans from $9 a month · Documentation